Key result
Higher day 4 post-MI GDF3 is linked to ~76% greater risk of adverse cardiac remodeling.
Why the study?
Excessive profibrotic response after myocardial infarction impairs optimal recovery, and the regulation of fibroblast proliferation by cardiac stromal cells is not fully understood.
Do circulating GDF3 levels at day 4 post-MI predict adverse cardiac remodeling at 6 months in patients with a first ST-elevation MI?
Cohort (n=80)
Yes
Do circulating GDF3 levels at day 4 post-MI predict adverse cardiac remodeling at 6 months in patients with a first ST-elevation MI?
Odds Ratio: 1.76 (95% CI 1.03–3)
p-value: p=0.037
GDF3 is a novel cardiokine secreted by cardiac stromal cells post-MI that promotes fibroblast proliferation and its circulating levels predict adverse fibrotic remodeling in STEMI patients.
No takes yet. Share an insight, caveat, or question.
Should not yet guide post-MI care; leaves open GDF3 as a target for preventing adverse remodeling.
Masurkar et al. (2021) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=80). Circulating GDF3 levels was evaluated on Adverse cardiac remodeling at 6 months post-MI (OR 1.76, 95% CI 1.03-3.00, p=0.037). Circulating GDF3 levels measured at day 4 post-myocardial infarction were significantly associated with an increased risk of adverse cardiac remodeling at 6 months (adjusted OR 1.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: